Statistics from Altmetric.com
- anticardiolipin antibodies
- lupus nephritis
- systemic lupus erythematosus
- antiphospholipid syndrome
- antiphospholipid antibodies
- thrombotic microangiopathy
The management of lupus nephritis (LN) and concomitant thrombotic microangiopathy (TMA), with or without antiphospholipid antibodies (aPL), remains controversial, and few studies are available to inform clinical management.1–4
The purpose of this multicentre retrospective study was to analyse the impact of anticoagulation (vitamin K antagonists (VKAs) and/or heparins) in addition to conventional immunosuppression on kidney outcomes (assessed at 12 months, according to the Kidney Disease: Improving Global Outcomes-KDIGOguidelines5) in patients with biopsy-proven LN and concomitant TMA.
Data source, population and statistical analysis are detailed in the online supplementary material 1. Anticoagulation was considered if given for at least three consecutive months after TMA diagnosis.
We retrospectively identified 97 patients with biopsy-proven LN and TMA (2007–2017). See online supplementary table 1 for clinical and demographic characteristics. Laboratory parameters were collected at the time of the biopsy. The mean age of patients was 38.9±15.2 years (13–69) and 85 females (87.6%). Most had proliferative LN (class …
Handling editor Josef S Smolen
Presented at Manuscripts based on work previously presented at the following conferences and published as a conference abstract.
ACR 2018: https://acrabstracts.org/abstract/clinical-outcomes-and-response-to-anti-thrombotic-treatment-among-patients-with-concomitant-lupus-nephritis-and-thrombotic-microangiopathy-a-multicenter-cohort-study/?msg=fail&shared=email
Contributors All the authors made substantial contributions to the conception and design of the work, the acquisition, analysis and interpretation of data. They all parteciapted to drafting the work or revising it critically for important intellectual content. All the authors gave the final approval of the version submitted.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.